3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
58
Neoplasm Metastasis
21
Carcinoma, Non-Small-Cell Lung
9
Stomach Neoplasms
8
Brain Neoplasms
8
Colorectal Neoplasms
7
Triple Negative Breast Neoplasms
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Endometrial Neoplasms
4
Salivary Gland Neoplasms
3
Recurrence
3
Neoplasms
3
Esophageal Neoplasms
3
Advanced Breast Cancer
3
Adenocarcinoma
3
Prostatic Neoplasms
2
Meningeal Carcinomatosis
2
HER2-positive Gastric Cancer
2
Colonic Neoplasms
2
Breast Cancer With Brain Metastasis
2
Advanced Solid Tumor
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Interventions
Cyclophosphamide
12
fludarabine phosphate
7
fludarabine
7
venetoclax
6
blinatumomab
6
Rituximab
5
Lenalidomide
5
Cytarabine
5
Dexamethasone
4
Blood Specimen Collection
4
Azacitidine
4
obinutuzumab
3
Radiotherapy
3
Melphalan
3
Immunotherapy, Adoptive
3
pembrolizumab
2
daratumumab
2
Neoadjuvant Therapy
2
Idarubicin
2
Chemotherapy, Adjuvant
2
Capecitabine
2
trastuzumab deruxtecan
1
tislelizumab
1
tisagenlecleucel
1
thymoglobulin
1
tetrathiomolybdate
1
talquetamab
1
tagraxofusp
1
sacituzumab govitecan
1
sabatolimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
trastuzumab deruxtecan
×
1 year
×
Clear all
NCT06663787
2026-05-13
HER2 CR
Nagoya City University
Active not recruiting
50 enrolled